MYCN-regulated microRNAs repress estrogen receptor-alpha (ESR1) expression and neuronal differentiation in human

Jakob Lovén1, Nikolay Zinin, Therese Wahlström

  • 1Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, SE-171 77 Stockholm, Sweden.

Insights

MYCN amplification in neuroblastoma disrupts estrogen signaling by upregulating miR-18a and miR-19a, which repress estrogen receptor-alpha (ESR1), hindering neuronal differentiation and promoting tumor growth.

Area of Science:

  • Oncology
  • Molecular Biology
  • Developmental Neuroscience

Background:

  • MYCN amplification is a key driver in human neuroblastoma (NB) pathogenesis.
  • Mechanisms of MYCN-driven NB progression remain incompletely understood.
  • MYCN proto-oncogene normally functions in neural crest development.

Purpose of the Study:

  • To elucidate the role of microRNAs (miRNAs) in MYCN-mediated neuroblastoma progression.
  • To investigate the functional consequences of MYCN-induced miRNA dysregulation on neuroblast differentiation.
  • To identify novel therapeutic targets for MYCN-amplified neuroblastoma.

Main Methods:

  • Expression analysis of miRNAs in NB tumors and cell lines.
  • Luciferase reporter assays to confirm miRNA targets.
  • Lentiviral manipulation of miRNA and ESR1 expression in NB cells.
  • Immunohistochemistry and bioinformatic analyses of patient data.

Main Results:

  • MYCN amplification induces a specific miRNA signature, including upregulation of miR-18a and miR-19a.
  • miR-18a and miR-19a directly target and repress estrogen receptor-alpha (ESR1).
  • Restoration of ESR1 or inhibition of miR-18a induces neuronal differentiation and growth arrest in NB cells.
  • High ESR1 expression correlates with improved event-free survival in NB patients.

Conclusions:

  • MYCN amplification disrupts normal estrogen signaling by downregulating ESR1 via induced miRNAs.
  • This disruption prevents the differentiation of primitive sympathetic cells, contributing to NB development.
  • Targeting miRNA-ESR1 axis offers a potential therapeutic strategy for MYCN-amplified neuroblastoma.